[
  {
    "ts": "2025-11-20T12:30:00+00:00",
    "headline": "Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates",
    "summary": "Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potentialIn September 2025, Sol-Gel announced Health Canada approval of EPSOLAYSol-Gel signed an additional agreement with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEO NESS ZIONA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering t",
    "url": "https://finance.yahoo.com/news/sol-gel-reports-third-quarter-123000367.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "1dcea8ba-24cb-310e-8bad-7bebdf0540a9",
      "content": {
        "id": "1dcea8ba-24cb-310e-8bad-7bebdf0540a9",
        "contentType": "STORY",
        "title": "Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates",
        "description": "",
        "summary": "Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potentialIn September 2025, Sol-Gel announced Health Canada approval of EPSOLAYSol-Gel signed an additional agreement with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEO NESS ZIONA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering t",
        "pubDate": "2025-11-20T12:30:00Z",
        "displayTime": "2025-11-20T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/a73f5df3002d616cb5db22325806b77d",
          "originalWidth": 1178,
          "originalHeight": 240,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_QEK5uYPnmSCjEAwVMZ4Vg--~B/aD0yNDA7dz0xMTc4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a73f5df3002d616cb5db22325806b77d.cf.webp",
              "width": 1178,
              "height": 240,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dQI8idvklHuBP871_KJcmg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a73f5df3002d616cb5db22325806b77d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sol-gel-reports-third-quarter-123000367.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sol-gel-reports-third-quarter-123000367.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            },
            {
              "symbol": "SLGL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]